Bimiralisib, CAS [[1225037-39-7]]

Produktübersicht

• Artikelname: Bimiralisib, CAS [[1225037-39-7]]
• Artikelnummer: TGM-T2265
• Hersteller Artikelnummer: T2265
• Alternativnummer: TGM-T2265-1MLX10MM(INDMSO),TGM-T2265-1MG,TGM-T2265-5MG,TGM-T2265-10MG,TGM-T2265-25MG,TGM-T2265-50MG,TGM-T2265-100MG
• Hersteller: TargetMol
• Kategorie: Biochemikalien
• Alternative Synonym: 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine , PQR309 , PI3K-IN-2

Produktbeschreibung

Bimiralisib (PI3K-IN-2) is an orally bioavailable pan inhibitor of PI3K and inhibitor of the mTOR, with potential antineoplastic activity. PI3K-IN-2 inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.

Produkteigenschaften

• Molekulargewicht: 411.38
• Reinheit: 99.88%
• CAS Nummer: [1225037-39-7]
• Formel: C17H20F3N7O2
• Target-Kategorie: mTOR|||PI3K|||S6 Kinase

Bilder

T2265